Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PtL2
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
PtL2 is a synthesized platinum complex derived from an α-amino acid, l-alanine, and a 2,3-dihydroxybenzaldehyde derived Schiff base (L). It has been characterized using various spectroscopic techniques including elemental analysis, IR, 1H NMR, 13C NMR, EPR, and ESI-MS. In vitro studies have shown that PtL2 exhibits significant cytotoxicity against human hepatocellular carcinoma (HepG2) cell lines. Its mechanism of action involves binding to proteins, such as human serum albumin (HSA), and generating reactive oxygen species (ROS), leading to concentration-dependent inhibition of cell viability.
- Other names
- platinum(II) l-alanine 2,3-dihydroxybenzaldehyde Schiff base complexPt(II) Schiff base complex
02
Targets
DNA
Beyond the preview
Go deeper on PtL2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PtL2.